English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A novel drug-carrier for paclitaxel entrapment entitled CMC/MATPP-PTX(CTP) was developed starting from the synthesis of MATPP that was grafted to CMC when EDC/NHS was served as coupling agent. Fourier Infrared Spectrometer (FT-IR) and  1 H Nuclear Magnetic Resonance ( 1 H NMR) characterized their constituents and structures information. Laser particle size analyzer (LPSA) and Scanning electron microscope (SEM) measured their size distribution and observed their morphology. Results showed substitution rate of CMC is up to 0.229 when the CMC: MATPP (mole ratio) is 1:0.016. CTP represents different microscale in distinct ratio of H 2 O/Ethanol or H 2 O/Acetone aqueous solution. SEM revealed the CTP possess a mean 500 ± 40 nm sizes. PTX loading and encapsulation rates are 14.6% and 8.9% when the ratio of CMC/MATPP:PTX (mole ratio) is 1:2, respectively. The cumulative release of paclitaxel can reach up to 59.75% within 5 h.

A Novel Drug-Carrier Based on CMC/MATPP-PTX(CTP) and In Vitro Release